PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MÉXICO
Authors:
- A Juarez-GarciaAJA Juarez-Garcia
- R Uc-CoyocRUR Uc-Coyoc
- G Hernandez-RiveraGHG Hernandez-Rivera
- S RangelSRS Rangel
- Mj TaylorMTMj Taylor
- G LitalienGLG Litalien
- B DonatoBDB Donato
- 31 October 2009
- journal article
- abstracts
- Published by Elsevier in Value in Health
- Vol. 12 (7) , A495